8-KEarnings & ResultsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Aug 3, 2026)

Filed August 3, 2026For Securities:VRTX

Summary

Vertex Pharmaceuticals Incorporated (VRTX) has filed an 8-K report on August 3, 2026, to disclose its financial results for the second quarter and first half of 2026. The core of this filing is a press release (Exhibit 99.1) detailing these financial outcomes, which investors should review for performance metrics. While the press release itself is incorporated by reference, it's important to note that the information within it is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934, meaning it doesn't carry the same legal liabilities as formal filings. However, it remains a crucial source of up-to-date information regarding the company's operational and financial standing as of June 30, 2026. Investors should pay close attention to the specific financial figures and operational updates provided in the attached press release. This includes revenue, profitability, and any forward-looking statements or guidance that may have been issued. The inclusion of the XBRL interactive data file further facilitates a deeper dive into the granular financial details. This report serves as Vertex's primary channel for communicating its recent performance to the market.

Key Highlights

  • 1Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on August 3, 2026, reporting Q2 and H1 2026 financial results.
  • 2The filing incorporates by reference a press release (Exhibit 99.1) dated August 3, 2026, containing detailed financial results.
  • 3Key financial performance indicators for the three and six months ended June 30, 2026, are provided in the press release.
  • 4The company disclosed its consolidated financial results as of June 30, 2026.
  • 5The press release, while incorporated, is not considered "filed" for Section 18 liability purposes.
  • 6An XBRL interactive data file (Exhibit 104) is included for enhanced data analysis.

Frequently Asked Questions

The primary purpose of this 8-K filing is to publicly disclose Vertex Pharmaceuticals' consolidated financial results for the second quarter and the first half of the fiscal year ended June 30, 2026, through an accompanying press release.

The detailed financial results are located in the press release attached as Exhibit 99.1 to this 8-K filing.

No, the information furnished in Exhibit 99.1 (the press release) is not deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, nor is it subject to the liabilities of that section. It also won't be automatically incorporated into other SEC filings unless specifically stated.

Exhibit 104 is the Cover Page Interactive Data File, which contains XBRL tags embedded within an Inline XBRL document. This allows investors to more easily access and analyze the financial data presented in the filing.